Lucid Group Inc vs McKesson Corporation — how do they compare? Lucid Group Inc trades at $6.72 (market cap $2.64B), while McKesson Corporation trades at $894.99 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 39.8× Lucid Group Inc's market cap, and McKesson Corporation pays a 0.42% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | MCK | |
|---|---|---|
Market Cap | $2.64B | $105.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.77 | $995.69 |
52-Week Low | $4.62 | $659.01 |
Enterprise Value | $5.54B | $111.67B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.
The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →